Company Overview and News

 
Big bonuses as Brian Gilbertson's Jupiter Mines re-enters ASX orbit

2018-03-25 theage.com.au
With Jupiter Mines preparing to the ASX boards again, CBD's primary concern was whether former BHP Billiton boss Brian Gilbertson was being kept in the style to which he was accustomed.

 
Big bonuses as Brian Gilbertson's Jupiter Mines re-enters ASX orbit

2018-03-25 smh.com.au
With Jupiter Mines preparing to the ASX boards again, CBD's primary concern was whether former BHP Billiton boss Brian Gilbertson was being kept in the style to which he was accustomed.

 
Capital Mining pulls out of cannabis investment

2017-11-17 australianmining.com.au
Junior Australian explorer Capital Mining has announced it is pulling out of medical cannabis investment through subsidiary Capital Cannabis Ltd (CCL), not to be confused with Californian equity company Cannabis Capital LLC.

 
Capital Mining says no to medical cannabis

2017-11-16 proactiveinvestors.com.au
Capital Mining Ltd's (ASX:CMY) shares have been suspended for the past three months pending an update on Capital Cannabis Limited.

1
Pot stock investors remain positive despite mixed results for sector

2017-11-03 theage.com.au
Australia's cannabis companies may have exploded onto the ASX in recent years, generating bemused interest and bad media puns, but their struggle to crack overseas markets means their performance has been decidedly patchy.

1
Pot stock investors remain positive despite mixed results for sector

2017-11-03 smh.com.au
Australia's cannabis companies may have exploded onto the ASX in recent years, generating bemused interest and bad media puns, but their struggle to crack overseas markets means their performance has been decidedly patchy.

 
Capital Mining remains in state of flux

2017-10-31 proactiveinvestors.com.au
Capital Mining Ltd (ASX:CMY) remains in a trading limbo pending an update on Capital Cannabis Limited.

 
Capital Mining remains hamstrung

2017-10-23 proactiveinvestors.com.au
Capital Mining Ltd's (ASX:CMY) ongoing suspension remains in place, which is now into its tenth week.

1
Capital Mining flounders under ASX spotlight

2017-10-04 theage.com.au
Beleaguered exploration minnow Capital Mining has fired back at queries raised by the ASX, saying the exchange's probe into its finances are outside the scope of its original inquiry.

1
Capital Mining flounders under ASX spotlight

2017-10-04 smh.com.au
Beleaguered exploration minnow Capital Mining has fired back at queries raised by the ASX, saying the exchange's probe into its finances are outside the scope of its original inquiry.

 
Capital Mining looks to new leadership as razor cuts through board

2017-09-27 proactiveinvestors.com.au
Capital Mining Ltd's (ASX:CMY) shares remain suspended pending an update on Capital Cannabis Limited (CCL), which is expected to be made on or before the 3rd October 2017.

 
Capital Mining maps timeline on Capital Cannabis Ltd

2017-09-25 proactiveinvestors.com.au
Capital Mining Ltd (ASX:CMY) has once again provided an update to its temporary suspension first initiated over a month ago, pending an update on Capital Cannabis Limited (CCL).

 
Capital Mining outlines expected timeline to medical cannabis update

2017-08-17 proactiveinvestors.com.au
Capital Mining Ltd (ASX:CMY) has requested and been granted another voluntary suspension by the ASX, pending an update on Capital Cannabis Limited.

 
Capital Mining calls for more time before medical cannabis details

2017-08-14 proactiveinvestors.com.au
Capital Mining Ltd (ASX:CMY) has been granted a voluntary suspension by the ASX this morning, following on from a trading halt.

 
Capital Mining Ltd calls for more time before medical cannabis details

2017-08-14 proactiveinvestors.com.au
Capital Mining Ltd (ASX:CMY) has been granted a voluntary suspension by the ASX this morning, following on from a trading halt.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...